News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™Dx System
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing Natick, MA – April
Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th
Natick, MA – December 7, 2023 – Pillar Biosciences is pleased to announce that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer,
Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting
NATICK, Mass. – November 8, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators
Beckman Coulter Life Sciences and Pillar Biosciences Announce NGS Application Development Pipeline for the Biomek NGeniuS System
Assays Focus on Accelerating Cancer Research INDIANAPOLIS – November 6, 2023 – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues
Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling
Research Use Only (RUO) NGS Kit will provide a simple, automatable, industry-leading liquid biopsy workflow NATICK, Mass. – September 19, 2023 – (PR NEWSWIRE) –
Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options
SAN DIEGO, JULY 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the